CCL

Összesen 56 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM037940
Első szerző:Adarichev, Vyacheslav A.
Cím:Antigen-induced differential gene expression in lymphocytes and gene expression profile in synovium prior to the onset of arthritis / Adarichev V. A., Vermes C., Hanyecz A., Ludanyi K., Tunyogi-Csapo M., Finnegan A., Mikecz K., Glant T. T.
Dátum:2006
ISSN:0891-6934
Megjegyzések:To explore early signature genes playing critical roles in the initial steps in an autoimmune murine model of rheumatoid arthritis (RA) (proteoglycan (PG)-induced arthritis; PGIA), we performed gene expression profiling of "arthritogenic" spleen cells stimulated with cartilage PG, and compared them to differentially expressed genes, identified in joints prior to the onset of arthritis, and then in the acute and chronic phases of the disease. A total of 280 genes were up-regulated and 226 genes were suppressed in in vitro PG-stimulated lymphocytes at a minimum of 2-fold expression change. Functional gene classification identified several major clusters of biological activity. Expression of immunoglobulin genes (66 transcripts) was downregulated by approximately 3.7-fold, whereas most of the other genes with immune/inflammation-associated functions such as interleukins (IL-1, -2, -4, -6, -10, -12, -16, -17), chemokine receptors and their ligands (Cxcl1, Ccl2, 7, 8, 9, 10, 22, Ccr2, Ccr5), and major components of the complement cascade were upregulated. Using adoptive disease transfer with stimulated lymphocytes into SCID mice, followed by gene expression profiling of SCID paws, indicated that 37 genes were differentially expressed in yet non-inflamed (pre-arthritic) paws; these genes were related mostly to chemokine, IFN-gamma and TNF-alpha signaling. However, the majority of differentially expressed immune response-related genes were silent in pre-arthritic joints, and only 12 genes were found differentially expressed both in antigen (PG)-stimulated lymphocytes and in the synovium prior to the onset of arthritis. Most of these "arthritis-initiation" genes belonged to chemokine mediated cell motility. Transcripts of chemokine receptor 5 (Ccr5), chemokine ligand 7 (Ccl7) and IFN-gamma-inducible proteins (Ifi47) and GTP-ase 1 were expressed at the highest levels in both antigen-stimulated lymphocytes and pre-inflamed synovium, which suggests a key role of these genes in both lymphocyte maturation and arthritis initiation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity. - 39 : 8 (2006), p. 663-673. -
További szerzők:Vermes Csaba Hanyecz Anita Ludányi Katalin (1975-) (immunológus) Tunyogi-Csapó Miklós Finnegan, Alison Mikecz Katalin Glant Tibor T.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM136431
Első szerző:Antal-Szalmás Péter (laboratóriumi szakorvos)
Cím:Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis / Antal-Szalmás Péter, Bencze Dóra, Demeter Sarolta, Pénzes-Daku Krisztina, Szabó Lilla, Tóth Beáta, Földesi Róza, Papp Mária, Nagy Gábor
Dátum:2026
ISSN:2589-9090
Megjegyzések:Primary biliary cholangitis (PBC), is a chronic autoimmune liver disease, characterized by cholangiopathy, cholestasis and in the long-term fibrosis, biliary cirrhosis and ultimately end-stage liver disease unless liver transplantation is applied. The diagnostics of PBC is based on biochemical tests, autoantibody measurements and liver histopathology. Abdominal ultrasound, later magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasound can be effective methods for imaging the intra- and extrahepatic bile ducts. Concerning autoantibodies, anti-mitochondrial (AMA) and PBC-specific antinuclear antibodies (ANA) are the front-line tests that can be identified by indirect immunofluorescence tests or solid-phase immunoassays. AMA and especially the AMA-M2 variant have a high sensitivity and specificity for PBC, while anti-gp210 and anti-sp100 (PBC-specific ANAs) have a lower sensitivity but very high specificity for the disease. Anti-centromere antibodies (ACA) can help in the diagnostics of PBC and some overlap syndromes. Novel emerging markers ? anti-hexokinase 1 and anti-Kelch-like 12 protein (anti-KLHL12) ? can help the identification of rare AMA- and ANA-negative PBC cases. There is cumulating evidence that beside diagnostics certain autoantibodies can provide information about the prognostics of PBC, can predict therapy response, furthermore, can act as activity marker in follow-up of the patients during therapy. We summarize here the most important data about the accepted and potential clinical applications of traditional and emerging new autoantibodies in PBC.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
autoimmune liver disease
primary biliary cholangitis
anti-mitochondrial antibody
anti-gp210
anti-sp100
anti-HK1
anti-KLHL-12
Megjelenés:Journal of Translational Autoimmunity. - 12 (2026), p. 1-15. -
További szerzők:Bencze Dóra (1992-) Demeter Sarolta (1987-) (orvos) Pénzes-Daku Krisztina (1978-) (biológus) Szabó Lilla (1993-) (molekuláris biológus) Lajszné Tóth Beáta (1978-) (molekuláris biológus) Földesi Róza (1967-) (klinikai laboratóriumi kutató, PhD hallgató) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Nagy Gábor (1974-) (laboratóriumi szakorvos, laboratóriumi hematológus és immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM015794
Első szerző:Arnson, Yoav
Cím:Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis a retrospective cohort study and review of the literature / Yoav Arnson, Howard Amital, Nancy Agmon-Levin, Danny Alon, María Sánchez-Castanón, Marcos López-Hoyos, Marco Matucci-Cerinic, Gabriella Szücs, Yinon Shapira, Zoltan Szekanecz, Yehuda Shoenfeld
Dátum:2011
ISSN:1568-9972
Megjegyzések:Low vitamin D serum concentrations have been reported in several autoimmune conditions. The study's aim was to explore such a relationship in a large multinational population of patients with systemic sclerosis (SSc) and to pursue possible clinical and laboratory correlates with vitamin D concentrations. 327 sera samples of European patients with SSc and 141 samples of compatible healthy controls were studied for vitamin D concentrations using the commercial kit LIAISON 25-OH vitamin D assay (Diasorin). Additionally, clinical parameters including the Rodnan skin score, diffusing lung capacity for carbon monoxide (DLCO), systolic pulmonary artery pressure (sPAP), forced vital capacity (FVC), and nailfold video capillaroscopic, erythrocyte sedimentation rate (ESR), anti-nuclear antibodies (ANA and scl70), rheumatoid factor (RF) were investigated. Vitamin D serum concentration was 13.5+/-9.0ng/ml (mean+/-standard deviation) in patients with SSc compared to 21.6+/-9.7ng/ml in a control group (p<0.001). A negative correlation between patients' age and vitamin D concentration (r=-0.2, p<0.05, n=96) was observed. An inverse relationship was found between skin involvement and vitamin D serum concentrations; Patients with a Rodnan skin score of 10 or lower (n=11) had a mean vitamin D concentration of 17.7+/-10.4ng/ml compared to patients with a score above 10 (n=28) 8+/-10.1ng/ml (p=0.02, by the Mann-Whitney test). In conclusion, Patients with SSc have significantly lower serum vitamin D concentrations compared to healthy controls; moreover fibrosis of the cutaneous tissue is inversely related to the vitamin D concentration.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity Reviews. - 10 : 8 (2011), p. 490-494. -
További szerzők:Amital, Howard Agmon-Levin, Nancy Alon, Danny Sánchez-Castanón, María Lopez-Hoyos, Marcos Matucci-Cerinic, Marco Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Shapira, Yinon Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:DOI
elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM003614
Első szerző:Baráth Sándor (biológus)
Cím:The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25(high)FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients / Baráth Sándor, Soltész Pál, Kiss Emese, Aleksza Magdolna, Zeher Margit, Szegedi Gyula, Sipka Sándor
Dátum:2007
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity. - 40 : 7 (2007), p. 521-528. -
További szerzők:Soltész Pál (1961-) (belgyógyász, kardiológus) Kiss Emese (1960-) (belgyógyász, immunológus) Aleksza Magdolna Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Sipka Sándor (1945-) (laboratóriumi szakorvos)
Internet cím:elektronikus változat
DOI
Borító:

5.

001-es BibID:BIBFORM078900
035-os BibID:(PMID)30992170
Első szerző:Betteridge, Zoe
Cím:Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients / Z. Betteridge, S. Tansley, G. Shaddick, H. Chinoy, R. G. Cooper, R. P. New, J. B. Lilleker, J. Vencovsky, L. Chazarain, K. Danko, M. Nagy-Vincze, L. Bodoki, M. Dastmalchi, L. Ekholm, I. E. Lundberg, N. McHugh, UKMyonet contributors
Dátum:2019
ISSN:0896-8411
Megjegyzések:OBJECTIVES: To determine prevalence and co-existence of myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs) and associated clinical characteristics in a large cohort of idiopathic inflammatory myopathy (IIM) patients. METHODS: Adult patients with confirmed IIM recruited to the EuroMyositis registry (n?=?1637) from four centres were investigated for the presence of MSAs/MAAs by radiolabelled-immunoprecipitation, with confirmation of anti-MDA5 and anti-NXP2 by ELISA. Clinical associations for each autoantibody were calculated for 1483 patients with a single or no known autoantibody by global linear regression modelling. RESULTS: MSAs/MAAs were found in 61.5% of patients, with 84.7% of autoantibody positive patients having a sole specificity, and only three cases (0.2%) having more than one MSA. The most frequently detected autoantibody was anti-Jo-1 (18.7%), with a further 21 specificities each found in 0.2-7.9% of patients. Autoantibodies to Mi-2, SAE, TIF1, NXP2, MDA5, PMScl and the non-Jo-1 tRNA-synthetases were strongly associated (p?<?0.001) with cutaneous involvement. Anti-TIF1 and anti-Mi-2 positive patients had an increased risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac involvement (OR 4.15). Interstitial lung disease was strongly associated with the anti-tRNA synthetases, anti-MDA5, and anti-U1RNP/Sm. Overlap disease was strongly associated with anti-PMScl, anti-Ku, anti-U1RNP/Sm and anti-Ro60. Absence of MSA/MAA was negatively associated with extra-muscular manifestations. CONCLUSIONS: Myositis autoantibodies are present in the majority of patients with IIM and identify distinct clinical subsets. Furthermore, MSAs are nearly always mutually exclusive endorsing their credentials as valuable disease biomarkers.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Autoantibodies
Autoimmune
Dermatomyositis
Myositis
Polymyositis
Megjelenés:Journal Of Autoimmunity. - 101 (2019), p. 48-55. -
További szerzők:Tansley, Sarah Shaddick, G. Chinoy, Hector Cooper, Robert G. New, Robert Paul Lilleker, James B. Vencovsky, Jiri Chazarain, L. Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Nagy-Vincze Melinda (1985-) (orvos) Bodoki Levente (1986-) (PhD hallgató) Dastmalchi, Maryam Ekholm, L. Lundberg, Ingrid McHugh, Neil UKMyonet contributors
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM057885
Első szerző:Bodoki Levente (PhD hallgató)
Cím:Four dermatomyositis-specific autoantibodies-anti-TIF1[gamma], anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort / Levente Bodoki, Melinda Nagy-Vincze, Zoltán Griger, Zoe Betteridge, Lászlóné Szöllősi, Katalin Dankó
Dátum:2014
ISSN:1568-9972
Megjegyzések:Idiopathic inflammatory myopathies (IIMs) are chronic systemic autoimmune diseases characterised by symmetrical, proximal muscle weakness. Dermatomyositis represents one subset of IIMs, in which skin rashes are present in addition to muscle weakness. Myositis-specific antibodies can only be detected in myositis, and they are directed against specific proteins found in the cytoplasm or in the nucleus of cells. With this case-based article, we introduce the recently detected anti-TIF1?, anti-NXP2, anti-SAE and anti-MDA5 antibodies that form various clinical groups. These antibodies could be detected in patients with dermatomyositis. The myositis-specific autoantibodies of three hundred and thirty-seven Hungarian patients with IIM were detected. Retrospective analysis of the clinical findings has also been introduced by revision of the medical history. We had twelve patients with anti-TIF1? positivity, four patients with anti-NXP2 positivity and four patients with anti-SAE positivity. We did not have any positive anti-MDA5 patients. The most relevant clinical findings were similar to those seen in previously published reports. Eleven of the twelve patients with anti-TIF1? positivity had classical dermatomyositis. Three of the twelve anti-TIF1? patients had cancer during the disease progression. This was two out of four for the anti-NXP2 subgroup and one in four for the anti-SAE subgroup. In two juvenile dermatomyositis cases, typical ulceration was seen in patients with anti-TIF1? positivity. The frequency of pulmonary fibrosis during the disease progression was 2/12, 1/4 and 1/4 in anti-TIF1?, anti-NXP2 and anti-SAE, respectively. Other extra-muscular manifestations, such as arthralgia, dysphagia, dysphonia and dyspnoea, were also detectable. The myositis subgroups determined by these myositis-specific autoantibodies differ from each other in their symptoms, prognosis and therapy responsiveness. Their detection is helpful for the preparation of an adequate treatment, but in daily diagnostic methods, these antibodies cannot be detected. By presenting our anti-TIF1?, anti-NXP2 and anti-SAE cases, we would like to highlight the clinical role of these antibodies.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity Reviews. - 13 : 12 (2014), p. 1211-1219. -
További szerzők:Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Betteridge, Zoe Szőllősi Lászlóné Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM114387
035-os BibID:(Scopus)85169934513 (WoS)001222938300001
Első szerző:Caporali, Roberto
Cím:Start RA Treatment - Biologics or JAK-Inhibitors? / Roberto Caporali, Sabino Germinario, Dorottya Kacsándi, Ernest Choy, Zoltán Szekanecz
Dátum:2024
ISSN:1568-9972
Megjegyzések:Janus Kinase inhibitors (JAKi) have been approved for the treatment of Rheumatoid Arthritis (RA) for several years. They are the first oral advanced treatment with efficacy similar to, if not greater than, biologic agents. Recently, concerns over their safety was raised by the results from Oral Surveillance trial suggesting that tofacitinib, one of the JAKi, was associated with higher cardiovascular adverse events and malignancies than TNF inhibitors (TNFi). Since then, regulatory authorities have added warnings to the labels of JAKi. On this purpose, whether rheumatologists should use JAKi as first line advance treatment has become a controversial topic. Some rheumatologists have argued that biologics should be first line advance treatment since there are extensive effectiveness and safety data. In addition, with the advent of biosimilar drugs, they are the most cost-effective treatment. On the other hand, JAKi are very efficacious and are generally safe apart from older and high-risk patients. When TNFi are contraindicated and in certain RA patients, especially when an oral drug is preferable, JAKi have significant advantage providing patients are involved in the decision-making process.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Autoimmunity Reviews. - 23 : 1 (2024), p. 1-4. -
További szerzők:Germinario, Sabino Kacsándi Dorottya Choy, Ernest Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

8.

001-es BibID:BIBFORM068029
Első szerző:Chen, Ji-Qing
Cím:The role of microRNAs in the pathogenesis of autoimmune diseases / Chen Ji-Qing, Papp Gábor, Szodoray Péter, Zeher Margit
Dátum:2016
ISSN:1568-9972
Megjegyzések:MicroRNAs (miRNAs) are single-stranded, endogenous non-coding small RNAs, ranging from 18 to 25 nucleotides in length. Growing evidence suggests that miRNAs are essential in regulating gene expression, cell development, differentiation and function. Autoimmune diseases are a family of chronic systemic inflammatory diseases. Recent findings on miRNA expression profiles have been suggesting their role as biomarkers in autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and Sjögren's syndrome. In this review, we summarize the characteristics of miRNAs and their functional role in the immune system and autoimmune diseases including systemic lupus erythematosus, primary Sjögren's syndrome, rheumatoid arthritis, systemic sclerosis, multiple sclerosis and psoriasis; moreover, we depict the advantages of miRNAs in modern diagnostics.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
MicroRNAs
Multiple sclerosis
Primary Sjögren's syndrome
Psoriasis
Rheumatoid arthritis
Systemic lupus erythematosus
Systemic sclerosis
Megjelenés:Autoimmunity Reviews. - 15 : 12 (2016), p. 1171-1180. -
További szerzők:Papp Gábor (1984-) (belgyógyász) Szodoray Péter (1973-) (belgyógyász, orvos) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Pályázati támogatás:OTKA-101470
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM033501
035-os BibID:(Scopus)34247591365 (WoS)000246340100001 (PMID)17453714
Első szerző:Csípő István (vegyész)
Cím:Determination of ligand binding capacity of soluble Fc gamma RII and Fc gamma RIII in sera of patients with SLE / Istvan Csipo, Sandor Barath, Emese Kiss, Gabriella Szucs, Gyula Szegedi, Maria Kavai
Dátum:2007
ISSN:0891-6934
Megjegyzések:BACKGROUND: Soluble, human low affinity Fcgamma receptors, such as sFcgammaRII and sFcgammaRIII, are known to play a pathologic role in different diseases. Sandwich ELISAs had previously been applied for the specific detection and determination of these soluble receptors. In these ELISAs, commercial monoclonal antibodies (Ab) were used as capture antibodies with monoclonal or polyclonal antibodies serving as detector Abs. Increased levels of cell-free FcgammaRIII have been detected in patients with lupus but the functions and levels of sFcgammaRII have not been fully characterized yet. OBJECTIVES: The aim of this work was to determine the ligand binding capacities and levels of soluble FcgammaRII and FcgammaRIII in sera of patients with systemic lupus erythematosus (SLE). Moreover, correlation between the levels of sFcgammaRII and sFcgammaRIII and the clinical activity of the disease were investigated. METHODS: Sera of 47 patients with SLE, and 51 healthy subjects were analyzed. In the newly developed indirect sandwich ELISAs commercial monoclonal anti-FcgammaRs are used as capture antibodies, and the ligand of FcgammaRII and FcgammaRIII, an artificial immune complex (IC), serves as a detection component replacing the second antibodies used in previous methods. RESULTS: The ligand binding capacity of both soluble FcgammaRII and sFcgammaRIII were elevated in the sera of SLE patients compared to control samples. This increase was significant in patients with the active disease (n = 30; p < 0.01). It was also revealed that a substantial part of the soluble Fcgamma receptors in these patients was bound in vivo to circulating IC. CONCLUSION: These newly developed ELISAs are probably more phisiologically relevant than other previous assays because they detect the circulating receptors on the basis their in vitro ligan binding capacities. Therefore this method can separately measure the levels of the soluble, free FcgammaRs and those bound circulating IC in vivo.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Autoimmunity. - 40 : 3 (2007), p. 165-168. -
További szerzők:Baráth Sándor (1977-) (biológus) Kiss Emese (1960-) (belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kávai Mária (1930-) (vegyész)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM035127
Első szerző:Doria, Andrea
Cím:Controversies in rheumatism and autoimmunity / Andrea Doria, Chaim Putterman, Piercarlo Sarzi-Puttini, Zoltán Szekanecz, Yehuda Shoenfeld
Dátum:2012
ISSN:1568-9972
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
rheumatism
autoimmunity
arthritis
endothelíal dysfunction
biologics
külföldön készült közlemény
Megjelenés:Autoimmunity Reviews. - 11 : 8 (2012), p. 555-557. -
További szerzők:Putterman, Chaim Sarzi-Puttini, Piercarlo Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM067428
Első szerző:Elshabrawy, Hatem A.
Cím:TLRs, future potential therapeutic targets for RA / Hatem A. Elshabrawy, Abdul E. Essani, Zoltán Szekanecz, David A. Fox, Shiva Shahrara
Dátum:2017
ISSN:1568-9972
Megjegyzések:Toll like receptors (TLR)s have a central role in regulating innate immunity and in the last decade studies have begun to reveal their significance in potentiating autoimmune diseases such as rheumatoid arthritis (RA). Earlier investigations have highlighted the importance of TLR2 and TLR4 function in RA pathogenesis. In this review, we discuss the newer data that indicate roles for TLR5 and TLR7 in RA and its preclinical models. We evaluate the pathogenicity of TLRs in RA myeloid cells, synovial tissue fibroblasts, T cells, osteoclast progenitor cells and endothelial cells. These observations establish that ligation of TLRs can transform RA myeloid cells into M1 macrophages and that the inflammatory factors secreted from M1 and RA synovial tissue fibroblasts participate in TH-17 cell development. From the investigations conducted in RA preclinical models, we conclude that TLR-mediated inflammation can result in osteoclastic bone erosion by interconnecting the myeloid and TH-17 cell response to joint vascularization. In light of emerging unique aspects of TLR function, we summarize the novel approaches that are being tested to impair TLR activation in RA patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Rheumatoid arthritis (RA)
Toll like receptors (TLR)s
Inflammation
Bone erosion
M1 macrophages
TH-17 cells
Megjelenés:Autoimmunity Reviews 16 : 2 (2017), p. 103-113. -
További szerzők:Essani, Abdul E. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Fox, David A. Shahrara, Shiva
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM057320
Első szerző:Erdei Annamária (belgyógyász)
Cím:Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy : a five-year follow-up study / Annamaria Erdei, Gyorgy Paragh, Peter Kovacs, Zsolt Karanyi, Ervin Berenyi, Laszlo Galuska, Agota Lenkey, Lajos Szabados, Ferenc Gyory, Bernadett Ujhelyi, Andras Berta, Judit Boda, Eszter Berta, Miklos Bodor, Annamaria Gazdag, Endre V. Nagy
Dátum:2014
ISSN:0891-6934
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity 47 : 8 (2014), p. 548-555. -
További szerzők:Paragh György (1953-) (belgyógyász) Kovács Péter (1947-) (belgyógyász, kardiológus, klinikai farmakológus) Karányi Zsolt (1961-) (biostatisztikus, bioinformatikus) Berényi Ervin (1964-) (radiológus) Galuska László (1946-) (belgyógyász, izotópdiagnoszta) Lenkey Ágota (1944-) (biológus) Szabados Lajos (1977-) (orvos) Győry Ferenc (1969-) (kardiológus) Ujhelyi Bernadett (1981-) (szemész) Berta András (1955-) (szemész, gyermekszemész) Boda Judit (belgyógyász, endokrinológus) Berta Eszter (1980-) (belgyógyász) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Gazdag Annamária (1979-) (belgyógyász) Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 3 4 5 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.